CRVO – cervomed inc. (US:NASDAQ)
Stock Stats
News
CervoMed Announces Late-Breaking Data at the 18th CTAD Conference Demonstrating Neflamapimod Significantly Slows Clinical Progression in Dementia with Lewy Bodies
CervoMed (NASDAQ:CRVO) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $31.00 price target on the stock.
CervoMed Presents New Plasma Biomarker Data That Indicates Neflamapimod Broadly Improves Neuroinflammation and Neurodegeneration in Dementia with Lewy Bodies (DLB)
CervoMed to Share New Data on Neflamapimod as a Treatment for Dementia with Lewy Bodies at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference
CervoMed (NASDAQ:CRVO) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $31.00 price target on the stock.
Form 4 CervoMed Inc. For: Oct 27 Filed by: Quigley David
Form 3 CervoMed Inc. For: Oct 27 Filed by: Quigley David
Form 8-K CervoMed Inc. For: Dec 01
Form 4 CervoMed Inc. For: Nov 17 Filed by: Gregoire Sylvie
Form 4 CervoMed Inc. For: Nov 17 Filed by: Winton Matthew
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.